Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, ...
Missing data in clinical trials remains an ongoing concern. With the expansion of data privacy efforts and the consequent inability to contact trial participants for follow-up, the magnitude and ...
Multicenter, randomized, controlled study will evaluate Company’s next-generation multichannel TMS technology in reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback